32: Idursulfase beta improves mobility and reduces organomegaly in MPS II

Idursulfase Beta — A New Therapeutic Option for MPS II with Strong Clinical Evidence

Article title:
Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: a phase 3, two-part study compared to a historical placebo cohort

Journal:
Genetics in Medicine

DOI:
10.1016/j.gim.2025.101460

Reference:
Sohn YB, Yang A, Kim MS, Kim J, Kim JS, Oh Y, Jin DK. Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: a phase 3, two-part study compared to a historical placebo cohort. Genetics in Medicine. 2025:101460. doi:10.1016/j.gim.2025.101460

Music:
Enjoy the music based on this article at the end of the episode.

License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/

Support:
Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00

Official website https://basebybase.com

On PaperCast Base by Base you’ll discover the latest in genomics, functional genomics, structural genomics, and proteomics.

Episode link: https://basebybase.com/episodes/idursulfase-beta-a-new-therapeutic-option-for-mps-ii-with-strong-clinical-evidence

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-06-05.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music
- transcript coverage: Audited the phase 3 two-part trial design, primary/secondary endpoints (6-MWT, GAGs/HS/DS, liver/spleen volumes, FVC), safety/ADAs/NAbs, PK, and manufacturing differences as depicted in the transcript.
- transcript topics: Phase 3 two-part trial design with historical placebo; 6-minute walk test efficacy; Urine GAG/HS/DS reductions; Liver and spleen volume changes; Pulmonary function (absolute FVC); Immunogenicity: anti-drug antibodies and neutralizing antibodies

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 8
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- 6-MWT improvement of 62.2 meters with idursulfase beta vs 7.3 meters with historical placebo
- Urine total GAG reduction of -71.13% with idursulfase beta vs +21.39% with historical placebo
- Liver volume reduction of -26.67% with idursulfase beta vs -0.80% with historical placebo
- Spleen volume reduction of -26.46% with idursulfase beta vs +7.2% with historical placebo
- Absolute FVC change showed no significant difference (p = 0.79)
- Anti-drug antibodies detected in most participants; persistent NAb ~17% vs ~62.5% in comparator

QC result: Pass.